HONG KONG – Japan's Takeda Pharmaceutical Co. Ltd. and India's Biological E Ltd. are collaborating to develop and deliver affordable combination vaccines. Under two licensing agreements, Takeda will transfer its measles and acellular pertussis vaccine technologies to Biological E, which will commercialize them in other markets.
HONG KONG – Japan’s Takeda Pharmaceutical Co. Ltd. and India’s Biological E Ltd. are collaborating to develop and deliver affordable combination vaccines. Under two licensing agreements, Takeda will transfer its measles and acellular pertussis vaccine technologies to Biological E, which will commercialize them in other markets.
HONG KONG – India's Central Drugs Standard Control Organization (CDSCO) has been streamlining regulations to standardize its rules on the market for pharmaceuticals.
HONG KONG – With $13.2 million in new financing, Tokyo-based oncology drug developer Anaeropharma Science Inc. now plans to focus on research and development of drug candidates that target hypoxic microenvironments of tumors by using recombinant Bifidobacterium.
HONG KONG – India's Central Drugs Standard Control Organization (CDSCO) has been streamlining regulations to standardize its rules on the market for pharmaceuticals.
HONG KONG – With $13.2 million in new financing, Tokyo-based oncology drug developer Anaeropharma Science Inc. now plans to focus on research and development of drug candidates that target hypoxic microenvironments of tumors by using recombinant Bifidobacterium.
